Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Buy” by Analysts

Quince Therapeutics, Inc. (NASDAQ:QNCX) has received an average rating of “Buy” from the six analysts that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $9.50.

Several equities analysts have issued reports on QNCX shares. Maxim Group assumed coverage on Quince Therapeutics in a research report on Thursday, November 7th. They set a “buy” rating and a $6.00 target price on the stock. RODMAN&RENSHAW raised Quince Therapeutics to a “strong-buy” rating in a report on Tuesday, October 29th. Rodman & Renshaw began coverage on Quince Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 target price for the company. EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, D. Boral Capital reiterated a “buy” rating and issued a $12.00 price objective on shares of Quince Therapeutics in a research note on Thursday, January 2nd.

Hedge Funds Weigh In On Quince Therapeutics

A hedge fund recently raised its stake in Quince Therapeutics stock. Geode Capital Management LLC lifted its holdings in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 24.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 339,125 shares of the company’s stock after purchasing an additional 66,170 shares during the period. Geode Capital Management LLC owned about 0.78% of Quince Therapeutics worth $263,000 as of its most recent SEC filing. 30.75% of the stock is owned by hedge funds and other institutional investors.

Quince Therapeutics Stock Down 0.3 %

QNCX stock opened at $1.59 on Monday. The stock has a market capitalization of $69.96 million, a PE ratio of -1.28 and a beta of 0.64. The company has a fifty day moving average of $1.86 and a 200-day moving average of $1.22. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.